<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0003613'>Antiphospholipid antibody</z:hpo> syndrome is associated with <z:hpo ids='HP_0004831'>recurrent thromboembolism</z:hpo> and the presence of antibodies directed against negatively charged <z:chebi fb="1" ids="16247">phospholipids</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Despite significant <z:hpo ids='HP_0100724'>hypercoagulability</z:hpo>, patients with the disorder often have elevated baseline activated partial thromboplastin times </plain></SENT>
<SENT sid="2" pm="."><plain>Although <z:chebi fb="5" ids="28304">heparin</z:chebi> is indicated for the treatment of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mp ids='MP_0005048'>thrombosis</z:mp>, <z:chebi fb="5" ids="28304">heparin</z:chebi> monitoring is complicated by laboratory test interference </plain></SENT>
<SENT sid="3" pm="."><plain>A practical treatment approach involves patient-specific screening for a reagent insensitive to the presence of the inhibitor, and determination of a reagent-specific therapeutic range in seconds that corresponds to <z:chebi fb="5" ids="28304">heparin</z:chebi> serum concentrations of 0.2-0.4 U/ml </plain></SENT>
<SENT sid="4" pm="."><plain>Other monitoring methods, including using the patient's baseline activated partial thromboplastin time or using an antifactor Xa activity assay, have not been reported or studied but may offer alternatives for <z:chebi fb="5" ids="28304">heparin</z:chebi> monitoring in patients with coagulation laboratory test interference associated with <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo> syndrome </plain></SENT>
</text></document>